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Background: Low plasma fibrinogen concentration is a predictor of poor outcome in major trauma patients. The
role of fibrinogen concentrate for rapidly increasing fibrinogen plasma levels in severe trauma is not well defined.
Methods: In this retrospective study we included severe trauma patients treated with fibrinogen concentrate alone
(FC group), fibrinogen concentrate with prothrombin complex concentrate (FC–PCC group) or fibrinogen
concentrate with PCC and fresh frozen plasma (FC–PCC–FFP group). PCC was generally administered as the second
step of intraoperative therapy, while FFP was only administered as a third step. All patients received ≥1 g
fibrinogen concentrate within 24 hours. Plasma fibrinogen concentration and ROTEM parameters upon emergency
room (ER) admission, intensive care unit (ICU) admission, and after 24 hours were analysed.
Results: Among 157 patients fulfilling the inclusion criteria, 83% were male; mean age was 44 years and median
injury severity score (ISS) was 29. Standard coagulation tests reflected increasing severity of coagulopathy with
increasing complexity of haemostatic therapy (highest severity in the FC–PCC–FFP group; p < 0.0001). Total 24-hour
fibrinogen concentrate dose also increased with complexity of haemostatic therapy. Plasma fibrinogen concentration
was maintained, with no significant difference between ER admission and ICU admission in all patient groups. FIBTEM
clot firmness at 10 minutes (CA10) was similarly maintained, albeit with a small increase in the FC–PCC group.
Fibrinogen concentration and FIBTEM CA10 were within the normal range in all groups at 24 hours. The ratio of
fibrinogen concentrate to red blood cells (g:U) ranged between 0.7:1.0 and 1.0:1.0.
Conclusion: Fibrinogen concentrate therapy maintained fibrinogen concentration and FIBTEM CA10 during the initial
phase of trauma care until ICU admission. After 24 hours, these parameters were comparable between the three
groups and within the normal range for each of them. Further studies are warranted to investigate the effect of
fibrinogen concentrate on clinical outcomes.
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In-hospital exsanguination has been reported in 26–39%
of all casualties in civilian trauma centres [1,2]. More-
over, it is estimated that up to 20% of trauma-associated
deaths are potentially preventable if early and rapid control
of blood loss and coagulopathy could be established [3].
Recent data from military and civilian trauma centres
revealed that early and high-volume fresh frozen plasma
(FFP) transfusion is associated with a favourable survival
rate [4,5]. However, several important shortcomings of
FFP transfusion should be considered. Firstly, for imme-
diate treatment pre-thawed FFP must be available. Out-
side busy trauma centres with high patient throughput
this is hard to establish. Secondly, coagulation factors do
not decrease uniformly during major bleeding. Fibrino-
gen has been identified as the most vulnerable coagula-
tion protein, being the first to reach critically low levels
[6]. This protein is required for both platelet aggre-
gation and fibrin formation [7]. Fibrinogen supplementa-
tion may also compensate for dilutional coagulopathy or
impaired haemostasis due to thrombocytopenia [8,9]
Low plasma fibrinogen concentration is common among
major trauma patients and associated with poor clinical
outcomes [10-13]. Importantly, FFP and solvent/deter-
gent-treated plasma (SD-plasma) contain only low levels
of fibrinogen [14]. Therefore, rapid normalization or even
maintenance of plasma fibrinogen concentration in severe
bleeding trauma patients is difficult when using plasma
alone [10,15]. Pre-thawed or freeze dried (lyophilized)
plasma can be provided much faster, but at present their
availability is limited and both have a similarly low concen-
tration of fibrinogen. Cryoprecipitate and purified human
fibrinogen concentrate represent potential alternatives to
plasma for maintaining or increasing the patient’s fibrino-
gen level, subject to these products’ availability. Cryopre-
cipitate has to be pooled (often just before administration);
it also contains variable amounts of fibrinogen, has to be
thawed before use and is not virus inactivated [16,17]. In
contrast, fibrinogen concentrate contains a well-defined
concentration of fibrinogen, has a good safety profile and
is immediately available for use [18]. A recent random-
ized, placebo-controlled study in complex cardiac surgery
revealed a significant reduction in allogeneic blood trans-
fusion in patients treated with fibrinogen concentrate
[19]. Several retrospective studies and case series have
reported improved outcomes using fibrinogen concentrate
in trauma [20-26].
Despite common use of fibrinogen concentrate in many
European trauma centres, little is known about its effect
on plasma fibrinogen concentration [21]. We retrospect-
ively investigated major trauma patients presenting at the
AUVA Trauma Centre, Salzburg who were treated with
fibrinogen concentrate as first-line coagulation therapy.
The aim was to compare plasma fibrinogen concentrationand FIBTEM clot amplitude at 10 minutes’ running time
(CA10) upon admission to the emergency room (ER), ad-
mission to the intensive care unit (ICU) and 24 hours
after ER admission. According to haemostatic treatment
administered, three groups of patients were investigated:
i. FC group, those receiving fibrinogen concentrate only,
ii. FC–PCC group, those receiving fibrinogen concentrate
and prothrombin complex concentrate (PCC) and iii. FC–
PCC–FFP group, those receiving fibrinogen concentrate,
PCC and FFP.
Methods
Following local ethics committee approval (415-EP/73/
197-2013) we performed a retrospective analysis of major
trauma patients admitted to the AUVA Trauma Centre
Salzburg between 2010 and 2012. The inclusion criterion
was administration of fibrinogen concentrate as first-line
coagulation therapy, which also included patients who
additionally received PCC and FFP. Exclusion criteria were
burns, pregnancy and participation in other studies. Pa-
tients receiving anticoagulation medication pre-trauma
were not excluded from the study as this information is
not always known when a patient arrives at the ER. Pa-
tients are usually treated with a ROTEM guided algorithm,
receiving fibrinogen concentrate and PCC according to
their actual needs.
Demographic data, laboratory data, trauma scores such
as injury severity score (ISS), new injury severity score
(NISS), Glasgow coma scale (GCS) and outcomes data
were obtained from the electronic trauma database.
Blood samples were drawn as soon as possible following
ER admission, either from arterial lines or, in less severe
cases, from venous lines. For coagulation monitoring,
citrated blood was collected in two standard coagulation
tubes. Viscoelastic testing was run within minutes on a
ROTEM analyser in the ER. The following tests were
performed: an extrinsically activated test using tissue fac-
tor (EXTEM) and a fibrin polymerization test (FIBTEM)
which inhibits platelets’ contribution to clot elasticity.
The following parameters were investigated: EXTEM
clotting time (CT, normal range 38–79 seconds), EXTEM
clot formation time (CFT, normal range 34–159 seconds),
EXTEM alpha angle (normal range 63–83°), EXTEM max-
imum clot firmness (MCF, normal range 50–72 mm) and
FIBTEM CA10 (normal range 7–23 mm).
A second citrated blood sample was drawn for standard
coagulation tests (SCTs) in the central laboratory. The fol-
lowing parameters were assessed after centrifugation of the
sample: fibrinogen concentration (Clauss Method, normal
range 200–450 mg/dL), prothrombin time (PT, normal
range 11.0–16.1 seconds) and activated partial thrombo-
plastin time (aPTT, normal range 23.7–34.9 seconds).
Blood cell count and blood gas analyses were performed
upon ER admission and ICU admission; haemoglobin
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mal range 150–350,000/μL) were also assessed. ROTEM
analyses or SCTs were performed upon ICU admission
for patients with suspected coagulopathy. We used the
timepoint “ICU” to describe assessments made at the
end of surgery or during the first few hours after ICU
admission.
SCTs were also run every morning at 7 am and, de-
pending on the patient’s condition, at 4 pm. For the
study, we applied the timepoint “24 hours” to describe
analyses performed at either 7 am or 4 pm, depending
which was closer to 24 hours after hospital admission.
Patients were treated according to our institutional algo-
rithm which was published recently [27]. Briefly, the indi-
cation for fibrinogen concentrate is to increase FIBTEM
CA10 to 10–12 mm for patients with low FIBTEM CA10
(<7 mm). Values below 7 mm indicate reduced fibrin
polymerization, often resulting from a low plasma fibrino-
gen level. Fibrinogen concentrate (HaemocomplettanW P;
CSL Behring, Marburg, Germany) is then administered, at
a dose of 2–6 g (2–4 g if initial FIBTEM CA10 4–6 mm;
6 g if initial FIBTEM CA10 0–3 mm). Platelet concen-
trate is transfused in patients whose EXTEM CA10 re-
mains low (<40 mm) after increasing FIBTEM CA10 to
10–12 mm. The algorithm also recommends considering
PCC if EXTEM CT is >80 seconds after raising FIBTEM
CA10 to 10–12 mm, or if EXTEM CA10 <30 mm [27].
ProthromplexW (Baxter, Vienna, Austria) was used in most
cases. According to our algorithm, tranexamic acid (TXA)
should be given if the patient is in shock or if ISS is
greater than 15 [27]. However, TXA was not included
in the algorithm until 2012, meaning that most of the
patients included in this study did not receive TXA
and that the use of this product increased during the ob-
servation period. Coagulation therapy data were obtained
from the anaesthesia records and ICU medical charts. FFP
was used mainly on individual discretion of the attending
anaesthetist, particularly in cases of ongoing major bleed-
ing, based on the consideration that factors not present
in PCC e.g., factor V are missing in the late stages of a
major trauma.
The target haemoglobin concentration during the ini-
tial operative procedure was 10 g/dL. In the postope-
rative phase, lower levels of 7–8 g/dL were accepted,
depending on the hemodynamic condition of the patient.
All transfused allogeneic blood products were recorded
in a database (DataLab, Bartels, Graz, Austria), in ac-
cordance with standard practice at our centre. Addition-
ally, the amount of cell-saver blood administered was
obtained from anaesthesia charts. Each 250 mL of cell-
saver blood transfused was considered equivalent to 1
unit of red blood cells (RBCs).
Mortality was defined as death within 30 days of ER
admission.Statistical analysis
The primary endpoint in this study was plasma fibrinogen
concentration and fibrin clot parameters on ICU admis-
sion. For all parameters, normality of the data distribution
was tested using the Kolmogorov-Smirnov test. Normally
distributed parameters were reported as mean ± standard
deviation, and those with non-normal distribution were
expressed as median and interquartile range (IQR; 25th
percentile – 75th percentile). For categorical variables,
p-values were derived from Fisher´s exact or the chi-
square test. For continuous variables including those
with time dependency, between-group differences were
analysed using analysis of variance (ANOVA) and the
Newman-Keuls test (comparisons of three groups) or the
Mann–Whitney U test (comparisons of two groups). For
within-group comparison of timepoints, the t-test or
Mann–Whitney U test was used.
Data were analysed for all patients with a value at the
timepoint of interest (e.g. patients who died within 24
hours were not included in 24-hour outcomes). Statis-
tical calculations were performed using GraphPad Prism
5.03 (GraphPad Software, La Jolla, CA, USA). The level
of significance was set at p < 0.05.
Results
Between January 2010 and December 2012, 160 patients
received fibrinogen concentrate as first-line coagulation
therapy within 24 hours of hospital admission. Three pa-
tients were excluded because they were enrolled in other
studies. Therefore, 157 patients were eligible for further
analyses.
The study population comprised 130 (83%) male and
27 (17%) female patients with a mean age of 44 ± 19
years. The median ISS was 29 (23–41), median NISS
was 34 (27–47) and median GCS was 11 (5–15). Imme-
diate operative intervention was performed in 139 (89%)
patients. Median ICU length of stay was 14 (5–23) days
and median hospital length of stay was 26 (14–40) days.
There were 85 patients in the FC group, 63 in the FC-
PCC group and 9 in the FC–PCC–FFP group (Table 1).
There were significant between-group differences in ISS
and NISS, with highest severity in the FC–PCC–FFP group
(p < 0.0001). Laboratory data for the three timepoints
are shown in Table 2. Significant between-group dif-
ferences were observed upon ER admission and ICU
admission in platelet count, PT, aPTT and fibrinogen
concentration, demonstrating worse coagulation status in
the FC–PCC group versus the FC group and worst status
in the FC–PCC–FFP group (Table 2). At 24 hours, sig-
nificant between-group differences were observed in
platelet count and aPTT, but there were no significant
between-group differences in most other parameters.
ROTEM data (EXTEM assay) demonstrated less pro-
nounced between-group differences (Figure 1). The most
Table 1 Clinical data upon emergency room (ER) admission of patients receiving fibrinogen concentrate (FC)
FC group (n = 85) FC–PCC group (n = 63) FC–PCC–FFP group (n = 9) p-value
Age (years) 40 (27–58) 45 (26–57) 49 (29–58) 0.99
Age >55 years, n (%) 24 (28%) 17 (27%) 2 (22%) 0.93
Male, n (%) 73 (86%) 51 (81%) 6 (67%) 0.31
Systolic BP (mmHg) 110 (90–131) 88 (75–125) 83 (75–105) 0.0068
Systolic BP ≤90 mmHg , n (%) 23 (27%) 32 (31%) 5 (56%) 0.0073
Temperature (°C) 35.2 (34.1–36.0) 35.7 (34.0–36.35) 35.9 (35.2–36.4) 0.39
ISS 27 (20–34) 34 (26–43) 50 (42–58) <0.0001
NISS 30 (26–41) 38 (28–50) 50 (43–58) 0.0002
ISS ≥16, n (%) 76 (89%) 63 (100%) 9 (100%) 0.018
ISS ≥25, n (%) 53 (62%) 48 (76%) 9 (100%) 0.025
GCS 12 (5–15) 10 (5–15) 7 (4–15) 0.58
pH 7.33 (7.28–7.38) 7.28 (7.22–7.35) 7.26 (7.17–7.35) 0.0025
BD (mmol/L) 3.7 (1.9–5.8) 5.6 (3.4–8.5) 5.8 (4.1–10.7) 0.0005
Lactate (mmol/L) 2.12 (1.56–3.48) 3.10 (2.27–5.45) 7.51 (4.51–8.78) 0.0001
Acute operative intervention*, n (%) 74 (87%) 57 (91%) 9 (100%) 0.45
Data are presented as median (interquartile range) or number (percentage of patients). p-values are derived from the ANOVA or chi-square test; significance
level p < 0.05.
*All types of intervention and damage control (e.g. orthopaedic surgery).
BD, base deficit; BP, blood pressure; ISS, injury severity score; NISS, new injury severity score; GCS, Glasgow coma scale.
FC group, patients receiving fibrinogen concentrate only; FC–PCC group, patients receiving fibrinogen concentrate and prothrombin complex concentrate;
FC–PCC–FFP group, patients receiving fibrinogen concentrate, prothrombin complex concentrate and fresh frozen plasma.
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FC–PCC–FFP group upon ICU admission, as well as low
EXTEM MCF and reduced alpha angle in the FC–PCC–
FFP group at the same timepoint. Severe coagulopathy in
the FC–PCC–FFP group was therefore demonstrated by
EXTEM in a similar manner to the laboratory data. Also
similar to the laboratory data, between-group differ-
ences in all EXTEM parameters reached statistical sig-
nificance upon ER admission and ICU admission but
not at 24 hours.
Transfusions of allogeneic blood products and coagula-
tion factor concentrates are shown in Table 3. In general,
transfusion requirements were highest in the FC–PCC–
FFP group and lowest in the FC group. The median 24-
hour dose of fibrinogen concentrate was 3 g (IQR 2–5 g;
range 2–11 g) in the FC group, 7 g (IQR 5–10 g; range 2–
21 g) in the FC–PCC group and 15 g (IQR 9–17 g; range
6–18 g) in the FC–PCC–FFP group. Thus, the total dose
of fibrinogen concentrate differed between groups in a
similar manner to ISS, with the highest values for dose
and ISS score in the FC–PCC–FFP group and lowest
values in the FC group. Plasma fibrinogen level did not
change significantly between ER admission and ICU ad-
mission in any of the three groups, even though the me-
dian dose of fibrinogen concentrate in the FC–PCC group
was more than double that in the FC group and median
dose in the FC–PCC–FFP group was 4-fold higher than
that in the FC group (p < 0.0001 for both comparisons)(Figure 2). FIBTEM CA10 increased significantly between
ER admission and ICU admission in the FC–PCC group
(p = 0.003), but not in either of the other groups. Plasma
fibrinogen concentration and FIBTEM CA10 were lower
in the FC–PCC–FFP group than in the other two groups
at ICU admission, despite the high intraoperative dose of
fibrinogen concentrate in the FC–PCC–FFP group. No
significant between-group differences were observed in ei-
ther of these parameters at 24 hours and, at this timepoint,
median values for both parameters in all three groups
were in the normal range.
The ratio of fibrinogen concentrate to RBC (g:U) for
the 24-hour period after ER admission was 1.0:1.0 in the
FC group, 0.9:1.0 in the FC–PCC group and 0.7:1.0 in
the FC–PCC–FFP group. Massive transfusion (≥10 U
RBC/24 hours) was observed in 40 patients: 7 (8%) in the
FC group, 24 (38%) in the FC–PCC group and 9 (100%) in
the FC–PCC–FFP group (p < 0.0001). The overall mortality
rate was 19% (30 patients): 8% (7) in the FC group, 29%
(18) in the FC–PCC group and 56% (5) in the FC–PCC–
FFP group (statistically significant between-group differ-
ence, p = 0.0001).
Discussion
To our knowledge this is the largest study of fibrinogen
concentrate administration in major trauma patients.
Coagulation therapy based on fibrinogen concentrate
was largely effective for maintaining plasma fibrinogen
Table 2 Blood cell count and standard coagulation tests
FC group FC–PCC group FC–PCC–FFP group p-value
n n n
Hemoglobin (g/dL)
ER 85 12.8 (11.2–13.9) 63 11.1 (8.8–12.7) 9 8.4 (6.5–11.6) <0.0001
ICU 70 8.8 (7.8–9.9) 44 9.3 (8.1–10.2) 9 8.0 (7.1–10.0) 0.20
24h 81 8.8 (7.8–9.9) 51 9.3 (8.1–10.2) 4 8.0 (7.1–10.0) 0.27
Platelet count (x 109/L)
ER 85 210 (176–251) 63 181 (141–215) 9 203 (162–295) 0.041
ICU 54 148 (108–179) 41 104 (65–126) 7 58 (35–88) <0.0001
24h 80 122 (95–162) 51 90 (63–111) 4 58 (37–75) <0.0001
PT (seconds)
ER 83 14.6 (13.4–15.8) 63 17.0 (15.3–19.3) 9 22.0 (17.7–27.9) <0.0001
ICU 34 17.5 (15.5–19.6) 31 21.0 (17.1–24.3) 7 28.6 (26.6–44.1) <0.0001
24h 70 16.2 (15.2–17.8) 48 16.7 (15.6–18.0) 4 16.6 (16.1–16.7) 0.49
aPTT (seconds)
ER 82 28.8 (26.0–31.7) 62 33.2 (28.0–43.5) 9 48.8 (35.3–96.5) <0.0001
ICU 42 32.7 (29.9–36.4) 31 46.9 (36.5–54.7) 8 180.0 (89.7–180.0) <0.0001
24h 77 37.7 (33.6–40.4) 49 40.2 (37.2–46.7) 4 45.5 (38.2–49.6) 0.0003
Fibrinogen (mg/dL)
ER 79 198 (156–225) 60 151 (112–199) 9 95 (83–161) <0.0001
ICU 41 188 (147–219) 32 162 (129–203) 8 119 (82–142) 0.0034
24h 76 266 (236–309) 49 274 (222–316) 4 269 (240–298) 0.96
Data are presented as median (interquartile range) or percentage of patients. p-values are derived from the ANOVA; significance level p < 0.05.
aPTT, activated partial thrombin time; PT, prothrombin time.
FC group, patients receiving fibrinogen concentrate only; FC–PCC group, patients receiving fibrinogen concentrate and prothrombin complex concentrate;
FC–PCC–FFP group, patients receiving fibrinogen concentrate, prothrombin complex concentrate and fresh frozen plasma.
Results were obtained at the following timepoints: upon admission to the emergency room (ER), admission to the intensive care unit (ICU) and 24 hours (24h)
after ER admission; n = number of patients with available data.
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FC and FC–PCC groups (94% of patients included in the
study), median fibrinogen levels were between 1.5 and
2.0 g/L as recommended in the European trauma Guide-
lines upon admission to the ER [28]. Assessment upon
admission to the ICU indicated that fibrinogen levels
were maintained within this range between the two
timepoints. Accordingly, median values for FIBTEM CA10
were also in the normal range at these timepoints. Only in
the FC–PCC–FFP group – the most severely injured
patients – were fibrinogen concentration and FIBTEM
CA10 below these ranges (at both time points). Import-
antly, plasma fibrinogen levels at 24 hours were in the nor-
mal range in all groups.
The most striking finding was that the administra-
tion of fibrinogen concentrate in all three groups, ei-
ther single-dose or repeated, did not lead to a surge in
plasma fibrinogen levels by the end of surgery and arrival
at ICU. However, one must consider that fibrinogen con-
centrate was given as haemostatic therapy to control bleed-
ing and to support continuous clot formation. Ongoingconsumption at the site of injury and surgery may be
assumed, raising the question of how best to main-
tain the patient’s plasma fibrinogen level within a specific
range (e.g. 1.5–2.0 g/L). Without fibrinogen concentrate
treatment, a decrease in plasma fibrinogen level may be
expected.
Plasma fibrinogen levels are not routinely measured at
most trauma facilities worldwide and the importance of
fibrinogen in major trauma patients has potentially been
underestimated. Chambers et al. observed that plasma
fibrinogen levels were critically low (<1 g/L) in most
trauma patients treated with a massive transfusion protocol
[10]. Low fibrinogen on admission was associated with
poor outcomes, and has been identified as an independent
predictor of mortality at 24 hours and 28 days (p < 0.001)
[15]. Despite this, until now neither the optimal concentra-
tion of fibrinogen in plasma nor the ideal ratio of fibrino-
gen to RBCs has been established. In a dilution model,
Bolliger et al. observed that clot formation was normalized
as plasma fibrinogen levels approached 2.0 g/L, and the au-
thors suggested this concentration as the minimum needed
Figure 1 EXTEM test results. Results from the extrinsically activated EXTEM assay, performed using ROTEM. Results were obtained at the
following timepoints: upon emergency room (ER) admission, intensive care unit (ICU) admission and 24 hours after ER admission. Data are
presented as median values; error bars represent interquartile ranges. CT, clotting time; CFT, clot formation time; MCF, maximum clot firmness. FC
group, patients receiving fibrinogen concentrate only; FC–PCC group, patients receiving fibrinogen concentrate and prothrombin complex
concentrate; FC–PCC–FFP group, patients receiving fibrinogen concentrate, prothrombin complex concentrate and fresh frozen plasma. *p < 0.05,
***p < 0.001, ns = not significant (unpaired t-test or Mann–Whitney U test).
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that with increasing amounts of fibrinogen the clot became
more resistant to pro-fibrinolytic breakdown stimulated by
tissue plasminogen activator [29]. Animal studies have re-
vealed that hypothermia decreases fibrinogen synthesis and
acidosis increases fibrinogen breakdown [30]; both of these
conditions are common in trauma. Low plasma fibrinogen
concentration has also been reported with hyperfibrinolysis
(HF), another common occurrence in trauma [7,31-33].
This may be related to the fact that plasmin not only
dissolves fibrin but (at high levels) also cleaves fibrino-
gen (hyperfibrinogenolysis) [31]. Data from the Clinical
Randomization of an Antifibrinolytic in Significant Haem-
orrhage (CRASH-2) study and the more recent Military
Application of Tranexamic Acid in Trauma Emergency Re-
suscitation (MATTERs) study highlighted the importance
of early antifibrinolytic therapy [34-36]. Haemostatic ther-
apy with either TXA or cryoprecipitate was associated with
a similar reduction in mortality [35]. Importantly, a com-
bination of both TXA and cryoprecipitate produced the
best survival rate [35].
The algorithm for managing trauma-induced coagulo-
pathy and bleeding at our centre [27] is based on first-lineadministration of coagulation factor concentrates. The
rationale for not giving FFP first-line is that coagula-
tion factor concentrates enable rapid and effective sup-
plementation of specific factors, with ROTEM analysis
allowing theragnostic treatment to be tailored according
to the patient’s actual needs. In contrast, with allogeneics-
based haemostatic therapy, several studies show that
FFP transfusion may be insufficient to maintain or in-
crease fibrinogen plasma concentration. Rourke et al.
measured plasma fibrinogen concentration after every
4 units of RBC transfusion. They showed that treat-
ment with RBC and FFP or platelets was insufficient to
maintain plasma fibrinogen at 1.5 g/L. Only additional
transfusion of cryoprecipitate resulted in maintenance
of fibrinogen levels [15].
Fibrinogen has a half-life of 2.6–3.7 days; therefore
the effect of exogenous fibrinogen concentrate may be
expected to last for a week or more post-treatment [7].
Furthermore, supra-physiologic levels of fibrinogen may be
expected postoperatively among trauma patients treated
with fibrinogen concentrate. However, in our study, doses
of 3 g, 6 g and 9 g of fibrinogen concentrate administered
at ER admission and/or during surgery did not significantly
Table 3 Hemostatic therapy administered during the study
FC group (n = 85) FC–PCC group (n = 63) FC–PCC–FFP group (n = 9) p-value
RBC (Units)
ER and intra-operative 2 (0–3) 5 (3–7) 11 (8–20) <0.0001
ICU 2 (0–3) 3 (1–5) 6.5 (5–12) <0.0001
24h 3 (2–6) 8 (5–11) 21 (18–26) <0.0001
Fibrinogen concentrate (g)
ER and intra-operative 3 (2–3) 6 (3–7) 9 (5–16) <0.0001
ICU 0 (0–2) 2 (0–4) 4 (0–6) 0.0006
24h 3 (2–5) 7 (5–10) 15 (9–17) <0.0001
PCC (Units)
ER and intra-operative 1200 (0–1800) 2400 (600–5100) 0.036
ICU 900 (0–1800) 1500 (0–2850) 0.34
24h 1800 (1200–2400) 4200 (3000–6150) 0.0029
FFP (Units)




ER and intra-operative 0 (0–0) 0 (0–0) 2 (0–2) <0.0001
ICU 0 (0–0) 0 (0–0) 2 (1–2) <0.0001
24h 0 (0–0) 0 (0–0) 4 (2–4) <0.0001
Tranexamic acid (g)
ER and intra-operative 0 (0–2) 0 (0–2) 0 (0–2) 0.0006
ICU 0 (0–0) 0 (0–0) 0 (0–0) ns
24h 0 (0–2) 0 (0–2) 0 (0–2) <0.0001
Data are presented as median (interquartile range). p-values are derived from the ANOVA or, for units of PCC, the Mann–Whitney U test; significance level p < 0.05.
FFP, fresh frozen plasma; ns, not significant; PCC, prothrombin complex concentrate; RBC, red blood cells.
FC group, patients receiving fibrinogen concentrate only; FC–PCC group, patients receiving fibrinogen concentrate and prothrombin complex concentrate;
FC–PCC–FFP group, patients receiving fibrinogen concentrate, prothrombin complex concentrate and fresh frozen plasma.
Results are presented for the following periods of time: while patients were in the emergency room (ER) and undergoing surgery, while patients were in the
intensive care unit (ICU), and the whole 24-hour period (24h) following ER admission.
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tic measurements made later on at the ICU. The mechan-
ism for this remains to be investigated, but it is likely to
relate to blood loss, dilution via fluid resuscitation and con-
sumption of the infused fibrinogen for clot formation at
the wound area during and/or early after surgery. The evo-
lution of fibrinogen levels after trauma could potentially
also be influenced by increased consumption or metabol-
ism of fibrinogen in the circulation, a shift of fibrinogen to
the extravascular space, or down-regulation of endogenous
fibrinogen synthesis.
All three study groups showed comparable plasma fi-
brinogen levels in the normal range (2.0–4.5 g/L [37,38])
during the first postoperative day. Importantly, the levels
after 24 hours are also comparable with the ones re-
ported by Schreiber et al. in trauma patients who did
not receive fibrinogen concentrate [38]. In addition, these
results are in agreement with data from a prospective studyof trauma patients where fibrinogen concentration at 24
hours was identical in patients who received fibrinogen
concentrate regardless of whether they had also received
FFP [39]. Similar observations have been made in other
settings – in four randomized controlled trials, 24-hour
plasma fibrinogen levels and FIBTEM MCF were similar
among patients treated with either fibrinogen concentrate
or allogeneic blood products [40-43]. One of these studies
found that shortly after fibrinogen concentrate infusion
there was an increase in plasma fibrinogen levels, which
was not apparent 2 hours after surgery [41].
It appears encouraging that hypercoagulability (gener-
ally defined by the surrogate marker of plasma fibrino-
gen concentration above the normal level) did not occur
24 hours after fibrinogen concentrate administration.
This lack of a sustained increase in plasma fibrinogen
levels suggests a low potential for late-onset complica-
tions, consistent with the reported low thrombogenic
Figure 2 Fibrinogen concentration and FIBTEM test results. For the fibrin-based FIBTEM assay, clot amplitude at 10 min running time (CA10)
is shown. Results were obtained at the following timepoints: upon admission to the emergency room (ER), upon admission to the intensive care
unit (ICU) and approximately 24 hours (24h) after ER admission. Data are presented as median values with interquartile ranges; error bars
represent minimum and maximum values. FIBTEM, extrinsically activated test of fibrin-based clotting (cytochalasin D inhibits platelet contribution
to clot strength); CA10, clot amplitude at 10 minutes. FC group, patients receiving fibrinogen concentrate only; FC–PCC group, patients receiving
fibrinogen concentrate and prothrombin complex concentrate; FC–PCC–FFP group, patients receiving fibrinogen concentrate, prothrombin
complex concentrate and fresh frozen plasma. *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant (unpaired t-test or Mann–Whitney U test).
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http://www.sjtrem.com/content/21/1/74potential of fibrinogen concentrate [18]. Importantly, the
desired effect of fibrinogen concentrate administration is
to ensure continuous haemostatic capacity and to control
bleeding satisfactorily, not primarily to maintain a specified
fibrinogen plasma level. Well-designed prospective, con-
trolled studies are necessary to confirm the clinical effect
of fibrinogen concentrate after major trauma [44,45].
Limitations
This was a retrospective study and potential errors are
inherent in this type of analysis. There is an established
treatment algorithm at our centre [27], but it cannot be
guaranteed that all treatment decisions were in accord-
ance with the algorithm. We were also not able to evalu-
ate the effect of artificial colloids in this study. For
example, hydroxyethyl starches interfere with the fibrin
polymerization process, and this results in low FIBTEM
clot amplitude [46].
Due to the retrospective study design, the potential side-
effects of fibrinogen concentrate (e.g. thrombogenicity)
could not be adequately assessed. A recent prospect-
ive randomized placebo-controlled study using fibrino-
gen concentrate in aortic surgery found no increase in
thromboembolic complications [19]. With a coagulation
concentrate-based approach to treatment, it should be
kept in mind that PCC is a thrombin generating drug. In
animal studies, high-dose PCC (50 U/kg bodyweight)
resulted in thromboemboli and, in 44% of the animals, dis-
seminated intravascular coagulation [47].
Conclusions
In the current study, fibrinogen concentrate therapy main-
tained stable plasma fibrinogen concentrations during
the initial phase of trauma care. In most patients,fibrinogen levels were within the range recommended in
the European trauma guidelines and FIBTEM CA10 was
in the normal range; the exception was the small group
with most severe bleeding who received additional PCC
and FFP, in whom lower levels were observed. At 24
hours, fibrinogen levels and FIBTEM CA10 were similar
in severe trauma patients treated with fibrinogen con-
centrate alone, fibrinogen concentrate followed by PCC
or fibrinogen concentrate followed by PCC and FFP,
and within the normal range in all three groups. Fur-
ther studies are warranted to elucidate the effects of fi-
brinogen supplementation on clinical outcomes in
trauma-related bleeding.
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